<DOC>
	<DOCNO>NCT00268957</DOCNO>
	<brief_summary>Approximately 207 patient chronic kidney disease ( CKD ) hemodialysis enter study approximately 26 center United States . This study aim evaluate safety efficacy sevelamer carbonate powder dose once-a-day ( QD ) large meal compare sevelamer hydrochloride tablet dose three-times-per-day ( TID ) meal . The total length participation approximately 24 week .</brief_summary>
	<brief_title>Study Compare Sevelamer Carbonate Powder Sevelamer Hydrochloride Tablets Patients With CKD Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>On three time per week hemodialysis three month longer Currently phosphate binder ( ) Considered compliant phosphate binder hemodialysis therapy Willing avoid intentional change diet fast diet Have follow document local laboratory measurement : a.Two recent consecutive serum phosphorus measurement ≥ 3.0 ≤ 6.5 ( 6.5 ) mg/dL within 60 day screen ; b.A recent intact parathyroid hormone ( iPTH ) measurement ≤ 800 pg/mL within 90 day screen Have follow central laboratory measurement : a.A serum phosphorus measurement &gt; 5.5 mg/dL randomization ( Week 0 ) ; b.A serum iPTH measurement ≤ 800 pg/mL screen Have participate investigational drug study within 30 day prior enrollment Level understand willingness cooperate visit procedure describe study personnel Willing able take sevelamer alone phosphate binder duration study Willing able maintain screening dose lipid medication duration study , except safety reason Willing able avoid antacid phosphate binder contain aluminum , magnesium , calcium lanthanum duration study unless prescribe even calcium supplement If female childbearing potential ( premenopausal surgically sterile ) , willing use effective contraceptive method throughout study , include barrier method , hormone , intrauterine device ( IUDs ) Life expectancy 12 month great Willing able provide inform consent Active bowel obstruction , dysphagia , swallow disorder , severe gastrointestinal ( GI ) motility disorder Active ethanol drug abuse , exclude tobacco use In opinion Investigator , subject poorly control diabetes mellitus , poorly control hypertension , active vasculitis , HIV infection , clinically significant unstable medical condition Use antiarrhythmic antiseizure medication use arrhythmia seizure disorder Known hypersensitivity sevelamer constituent study drug Pregnant breastfeeding Evidence active malignancy except basal cell carcinoma skin Unable comply requirement study Any condition , opinion Investigator , prohibit subject 's inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Kidney</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Chronic Renal Insufficiency</keyword>
</DOC>